Frequencies and geographic distributions of genetic mutations in transthyretin- and non-transthyretin-related familial amyloidosis

Clinical Genetics

Volumn 88, Issue 4, 2015, Pages 396-400

  Zhen, D B ^a   Swiecicki, P L ^a   Zeldenrust, S R ^b   Dispenzieri, A ^b   Mauermann, M L ^c   Gertz, Morie A ^b  

^a Department of Internal Medicine ^*  (United States)

^b Oncology and Stem Cell Transplantation   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Amyloidosis; Apolipoprotein; Fibrinogen; Gelsolin; Hereditary; Lysozyme; Mutation; Transthyretin

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; FIBRINOGEN; FIBRINOGEN A ALPHA; GELSOLIN; LYSOZYME; UNCLASSIFIED DRUG; PREALBUMIN;

ARTICLE; CROSS-SECTIONAL STUDY; DNA SEQUENCE; FAMILIAL AMYLOIDOSIS; FAMILY HISTORY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; GEOGRAPHIC DISTRIBUTION; HUMAN; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; NON TRANSTHYRETIN RELATED FAMILIAL AMYLOIDOSIS; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETROSPECTIVE STUDY; TRANSTHYRETIN RELATED FAMILIAL AMYLOIDOSIS; UNITED STATES; DNA MUTATIONAL ANALYSIS; EPIDEMIOLOGY; FAMILIAL AMYLOID POLYNEUROPATHY; FEMALE; GENETIC PREDISPOSITION; GENETICS; GEOGRAPHY; MALE; MISSENSE MUTATION;

AMYLOID NEUROPATHIES, FAMILIAL; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GEOGRAPHY; HUMANS; MALE; MUTATION, MISSENSE; PREALBUMIN; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84941745693     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/cge.12500     Document Type: Article

References (25)

1. Plante-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol 2011: 10 (12): 1086-1097.
2. Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 2007: 36 (4): 411-423.
3. Kanda Y, Goodman DS, Canfield RE, Morgan FJ. The amino acid sequence of human plasma prealbumin. J Biol Chem 1974: 249 (21): 6796-6805.
4. Saraiva MJ. Transthyretin mutations in hyperthyroxinemia and amyloid diseases. Hum Mutat 2001: 17 (6): 493-503.
5. Hornsten R, Pennlert J, Wiklund U, Lindqvist P, Jensen SM, Suhr OB. Heart complications in familial transthyretin amyloidosis: impact of age and gender. Amyloid 2010: 17 (2): 63-68.
6. Lobato L, Beirao I, Silva M et al. End-stage renal disease and dialysis in hereditary amyloidosis TTR V30M: presentation, survival and prognostic factors. Amyloid 2004: 11 (1): 27-37.
7. Bergen HR 3rd, Zeldenrust SR, Butz ML et al. Identification of transthyretin variants by sequential proteomic and genomic analysis. Clin Chem 2004: 50 (9): 1544-1552.
8. Coelho T, Maurer MS, Suhr OB. THAOS: the Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin 2013: 29 (1): 63-76.
9. Araki S, Ando Y. Transthyretin-related familial amyloidotic polyneuropathy: progress in Kumamoto, Japan (1967-2010). Proc Jpn Acad Ser B Phys Biol Sci 2010: 86 (7): 694-706.
10. Conceicao I. Clinical features of TTR-FAP in Portugal. Amyloid 2012: 19 (Suppl 1): 71-72.
11. Suhr OB, Svendsen IH, Andersson R, Danielsson A, Holmgren G, Ranlov PJ. Hereditary transthyretin amyloidosis from a Scandinavian perspective. J Intern Med 2003: 254 (3): 225-235.
12. Ando Y, Coelho T, Berk JL et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis 2013: 8: 31.
13. Jacobson DR, Pastore R, Pool S et al. Revised transthyretin Ile 122 allele frequency in African-Americans. Hum Genet 1996: 98 (2): 236-238.
14. Yamashita T, Hamidi Asl K, Yazaki M, Benson MD. A prospective evaluation of the transthyretin Ile122 allele frequency in an African-American population. Amyloid 2005: 12 (2): 127-130.
15. Leibou L, Frand J, Sadeh M et al. Clinical and genetic findings in eight Israeli patients with transthyretin-associated familial amyloid polyneuropathy. Isr Med Assoc J 2012: 14 (11): 662-665.
16. Levy E, Haltia M, Fernandez-Madrid I et al. Mutation in gelsolin gene in Finnish hereditary amyloidosis. J Exp Med 1990: 172 (6): 1865-1867.
17. Maury CP, Kere J, Tolvanen R, de la Chapelle A. Finnish hereditary amyloidosis is caused by a single nucleotide substitution in the gelsolin gene. FEBS Lett 1990: 276 (1-2): 75-77.
18. Gursky O, Mei X, Atkinson D. The crystal structure of the C-terminal truncated apolipoprotein A-I sheds new light on amyloid formation by the N-terminal fragment. Biochemistry 2012: 51 (1): 10-18.
19. Hamidi Asl K, Liepnieks JJ, Nakamura M, Parker F, Benson MD. A novel apolipoprotein A-1 variant, Arg173Pro, associated with cardiac and cutaneous amyloidosis. Biochem Biophys Res Commun 1999: 257 (2): 584-588.
20. Coriu D, Dispenzieri A, Stevens FJ et al. Hepatic amyloidosis resulting from deposition of the apolipoprotein A-I variant Leu75Pro. Amyloid 2003: 10 (4): 215-223.
21. Benson MD. Ostertag revisited: the inherited systemic amyloidoses without neuropathy. Amyloid 2005: 12 (2): 75-87.
22. Benson MD, Liepnieks J, Uemichi T, Wheeler G, Correa R. Hereditary renal amyloidosis associated with a mutant fibrinogen alpha-chain. Nat Genet 1993: 3 (3): 252-255.
23. Uemichi T, Liepnieks JJ, Benson MD. Hereditary renal amyloidosis with a novel variant fibrinogen. J Clin Invest 1994: 93 (2): 731-736.
24. Uemichi T, Liepnieks JJ, Yamada T, Gertz MA, Bang N, Benson MD. A frame shift mutation in the fibrinogen A alpha chain gene in a kindred with renal amyloidosis. Blood 1996: 87 (10): 4197-4203.
25. Hamidi Asl L, Liepnieks JJ, Uemichi T et al. Renal amyloidosis with a frame shift mutation in fibrinogen a alpha-chain gene producing a novel amyloid protein. Blood 1997: 90 (12): 4799-4805.